Table 1.
Treatment regimens for prevention of CINV used in the model
| Antiemetic regimen | CINV prophylaxis | Day 1a
|
Days 2 and 3 | |
|---|---|---|---|---|
| Before chemotherapy | 8 hours after 1st dose | |||
| Aprepitant regimen | Aprepitant | 125 mg PO once | – | 80 mg PO OD |
| Ondansetron | 8 mg PO | 8 mg PO | – | |
| Dexamethasone | 12 mg PO once | – | – | |
| UK comparator regimen | Ondansetron | 8 mg PO once | – | – |
| Dexamethasone | 20 mg IV once | – | 8 mg PO OD | |
| Metoclopramide | – | – | 20 mg PO TID | |
| Clinical trial control regimen23 | Ondansetron | 8 mg PO | 8 mg PO | 8 mg PO BID |
| Dexamethasone | 20 mg PO once | – | – | |
| Alternative UK comparator regimen (sensitivity analysis) | Ondansetron | 8 mg PO once | – | 8 mg PO BID |
| Dexamethasone | 20 mg IV once | – | 8 mg PO OD | |
| Metoclopramide | – | – | 20 mg TID | |
Note:
a
Chemotherapy was administered on day 1.
Abbreviations: CINV, chemotherapy-induced nausea and vomiting; PO, oral; OD, once daily; IV, intravenous; TID, three times a day; BID, two times daily; UK, United Kingdom.